RT Journal Article
SR Electronic
T1 Governance is key to controlling SARS-CoV-2’s vaccine resistance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.26.22275649
DO 10.1101/2022.05.26.22275649
A1 Okamoto, Kenichi W.
A1 Chaves, Luis F.
A1 Wallace, Rodrick
A1 Wallace, Robert G.
YR 2022
UL http://medrxiv.org/content/early/2022/05/30/2022.05.26.22275649.abstract
AB Little attention has been paid to governance’s impacts on the evolution of SARS-CoV-2, the virus that causes COVID-19. To evaluate such impacts on the evolution of vaccine resistance, we analyzed a stochastic compartmental model to quantify the risk a mutant strain capable of evading immunity emerges post-vaccine rollout. We calibrated the model with publicly available data for four territories in the Western Hemisphere qualitatively differing in pandemic interventions. The model shows an immune-evading strain to be readily selected over all infectivities in Texas. In Panama, only a high level of transmission permits immune evasion to evolve. No invasion appears likely in Costa Rica and Uruguay. Programs combining pharmaceutical and nonpharmaceutical interventions are best positioned to remove the epidemiological space SARS-CoV-2 needs to evolve vaccine resistance.One Sentence Summary Modes of governance and production help set the evolutionary trajectories of vaccine resistance in SARS-CoV-2 before vaccine campaigns begin.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at github.com/kewok/immune_evasion https://github.com/kewok/immune_evasion